Pharming Group N.V. (PHARM.AS)

Netherlands · Healthcare · EUR

Key financials

ROE: 1.14%; 2025 (actual)
ROA: 0.63%; 2025 (actual)
Gross Margin: 87.9%; 2025 (actual)
Net Margin: 0.76%; 2025 (actual)
Total Assets: €499.96M; 2025 (actual)
Net Income: €2.85M; 2025 (actual)
Valuation: €1,009.30M; 2026 (forecast)
Stock Price: €1.43; 2026 (forecast)

Historical & projected performance

Reported figures and Equlion model projections for the next 5 years.

Metric	2025 (actual)	2026 (forecast)	2027	2028	2029	2030	2031
ROE	1.14%	3.24%	4.85%	5.27%	5.95%	6.46%	6.54%
Sector average	-	6.61%	7.26%	7.46%	8.09%	8.5%	8.38%
ROA	0.63%	1.83%	2.81%	3.07%	3.45%	3.74%	3.82%
Sector average	-	3%	3.54%	3.74%	4.1%	4.35%	4.38%
Gross Margin

Amounts in EUR (millions); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Stock price and valuation carry no data date: they are the Equlion model's estimate for 2026. Projections are model estimates, not investment advice.

Want the full financial forecast report for Pharming Group N.V.? It covers the balance sheet, income statement and Equlion model projections.

Net Margin	0.76%	2.46%	3.49%	3.53%	3.61%	3.74%	3.8%
Sector average	-	4.38%	4.98%	4.98%	5.03%	5.18%	5.24%

Total Assets	€499.96M	€467.98M	€487.29M	€514.30M	€549.76M	€584.54M	€616.25M
Sector average	-	€13,584.49M	€14,235.95M	€15,314.00M	€16,798.87M	€18,256.69M	€19,570.65M

Net Income	€2.85M	€8.86M	€13.44M	€15.36M	€18.35M	€21.19M	€22.92M
Sector average	-	€562.90M	€588.83M	€647.75M	€757.18M	€866.32M	€932.30M

Valuation	-	€1,009.30M	€996.23M	€979.65M	€957.48M	€930.03M	€899.45M
Sector average	-	€11,440.99M	€11,271.41M	€11,072.13M	€10,816.20M	€10,503.92M	€10,158.53M

Stock Price	-	€1.43	€1.41	€1.38	€1.35	€1.31	€1.27
Sector average	-	€11.90	€11.72	€11.51	€11.25	€10.92	€10.57